Compared with basal insulin, initiation of GLP-1 RAs in a real-world setting is associated with a reduced risk of albuminuria progression and possible mitigation of kidney function loss in patients with T2D and mostly preserved kidney function. The gene discussed is INS; the disease is type 2 diabetes mellitus.